MTD vs. NBIX: Mettler-Toledo vs. Neurocrine Biosciences Stock Comparison
How do Mettler-Toledo (MTD) and Neurocrine Biosciences (NBIX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Mettler-Toledo (MTD) and Neurocrine Biosciences (NBIX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MTD is classified in Life Sciences Tools & Services while NBIX is classified in Biotechnology.
| Profile Item | MTD | NBIX |
|---|---|---|
| Name | Mettler-Toledo International Inc. | Neurocrine Biosciences, Inc. |
| Country/Region | Switzerland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| GICS Sub-Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 34.25 billion USD | 16.66 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | November 14, 1997 | May 23, 1996 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | MTD | NBIX |
|---|---|---|
| Total Return (1Y) | 21.58% | 9.40% |
| Total Return (3Y, Annualized) | 19.54% | 14.12% |
| Total Return (5Y, Annualized) | 2.36% | 12.61% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | MTD | NBIX |
|---|---|---|
| Volatility (1Y, Annualized) | 31.70% | 35.05% |
| Beta (5Y) | 1.15 | 0.29 |
| Max Drawdown (5Y) | -43.47% | -42.89% |
| Avg. Volume (3M) | 197.80K | 1.31M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | MTD | NBIX |
|---|---|---|
| Sharpe Ratio (1Y) | 0.55 | 0.15 |
| Sortino Ratio (1Y) | 0.75 | 0.22 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Neurocrine Biosciences (NBIX) earns 20.42% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- MTD
- --
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.42%
- Max
- 109.18%
- NBIX
- 20.42%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Mettler-Toledo (MTD) at 22.25% and Neurocrine Biosciences (NBIX) at 18.98% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.25%
- MTD
- 22.25%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.98%
- NBIX
- 18.98%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Mettler-Toledo (MTD) at 28.70% and Neurocrine Biosciences (NBIX) at 31.98% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.70%
- Max
- 83.12%
- MTD
- 28.70%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.98%
- Max
- 83.12%
- NBIX
- 31.98%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | MTD | NBIX |
|---|---|---|
| ROE (TTM) | -- | 20.42% |
| ROA (TTM) | 20.09% | 12.45% |
| Net Margin (TTM) | 22.25% | 18.98% |
| Operating Margin (TTM) | 28.70% | 31.98% |
| Gross Margin (TTM) | 59.16% | 64.67% |
Growth
Revenue Growth
Both Mettler-Toledo (MTD) at 3.98% and Neurocrine Biosciences (NBIX) at 21.45% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Mettler-Toledo (MTD) at 3.88% and Neurocrine Biosciences (NBIX) at 41.95% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | MTD | NBIX |
|---|---|---|
| Revenue Growth (YoY) | 3.98% | 21.45% |
| Revenue Growth (3Y CAGR) | 0.90% | 24.32% |
| EPS Growth (YoY) | 3.88% | 41.95% |
| EPS Growth (3Y CAGR) | 3.06% | 44.12% |
Financial Strength
Current Ratio (MRQ)
Both Mettler-Toledo (MTD) at 1.10 and Neurocrine Biosciences (NBIX) at 2.04 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.10
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MTD
- 1.10
- Min
- 0.10
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.04
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- NBIX
- 2.04
- Min
- 0.10
Debt / Equity (MRQ)
Neurocrine Biosciences (NBIX) at 0.12 is near its industry mid-range for debt-to-equity ratio, while Mettler-Toledo (MTD) at 26.06 sits above its benchmark range, pointing to a heavier debt load relative to equity.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.06
- MTD
- 26.06
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.12
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- NBIX
- 0.12
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | MTD | NBIX |
|---|---|---|
| Current Ratio (MRQ) | 1.10 | 2.04 |
| Debt / Equity (MRQ) | 26.06 | 0.12 |
| Net Debt / EBITDA | 1.58 | -0.27 |
Dividends
Dividend Yield (TTM)
Neither Mettler-Toledo (MTD) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MTD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NBIX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Mettler-Toledo (MTD) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MTD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NBIX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | MTD | NBIX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Both Mettler-Toledo (MTD) at 37.38 and Neurocrine Biosciences (NBIX) at 24.43 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.38
- Max
- 85.34
- Q3
- 43.46
- MTD
- 37.38
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.43
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- NBIX
- 24.43
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Mettler-Toledo (MTD) at 8.16 and Neurocrine Biosciences (NBIX) at 4.50 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.16
- Max
- 58.18
- Q3
- 25.77
- MTD
- 8.16
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.50
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- NBIX
- 4.50
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Neurocrine Biosciences (NBIX) at 4.30 sits near its industry’s typical P/B ratio, while Mettler-Toledo (MTD) at 442.71 prices above its benchmark range — MTD looks rich relative to book.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
442.71
- MTD
- 442.71
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.30
- Max
- 13.53
- Q3
- 6.54
- NBIX
- 4.30
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | MTD | NBIX |
|---|---|---|
| P/E Ratio (TTM) | 37.38 | 24.43 |
| P/S Ratio (TTM) | 8.16 | 4.50 |
| P/B Ratio (MRQ) | 442.71 | 4.30 |
| Free Cash Flow Yield (TTM) | 1.97% | 6.11% |